SCHEMBL1984728

SCHEMBL1984728

O=C(O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)CCC1=O

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNMT1 P26358 3/20 0.75
KMT2A Q03164 3/20 0.73
PKM P14618 2/20 0.73
CYP2C19 P33261 1/20 0.73
DNMT3B Q9UBC3 1/20 0.73
MAPT P10636 3/20 0.66
MEN1 O00255 2/20 0.66
GAA P10253 1/20 0.63
STAT3 P40763 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.59
ALDH1A1 P00352 1/20 0.58
KDM4E B2RXH2 2/20 0.58
APAF1 O14727 1/20 0.58
POLB P06746 1/20 0.58
RECQL P46063 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
LMNA P02545 1/20 0.58
MPO P05164 1/20 0.58
TSHR P16473 1/20 0.58
BLM P54132 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3081901 1.00 DNMT1 (0.75) DNMT1KMT2APKMCYP2C19DNMT3B
SCHEMBL2445932 1.00 DNMT1 (0.75) DNMT1KMT2APKMCYP2C19DNMT3B
SCHEMBL19244073 0.96 DNMT1 (0.73) DNMT1KMT2APKMCYP2C19DNMT3B
SCHEMBL2443777 0.96 DNMT1 (0.73) DNMT1KMT2APKMCYP2C19DNMT3B
Tryptophan SCHEMBL8845198 0.93 KMT2A (0.71) DNMT1KMT2APKMCYP2C19DNMT3B
SCHEMBL4214992 0.92 DNMT1 (0.75) DNMT1KMT2APKMCYP2C19DNMT3B
SCHEMBL3089375 0.88 DNMT1 (0.58) DNMT1KMT2APKMCYP2C19DNMT3B
SCHEMBL3080269 0.88 DNMT1 (0.58) DNMT1KMT2APKMCYP2C19DNMT3B
Potassium Ion SCHEMBL2438113 0.88 DNMT1 (0.58) DNMT1KMT2APKMCYP2C19DNMT3B
SCHEMBL23683013 0.86 DNMT1 (1.00) DNMT1KMT2APKMCYP2C19DNMT3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110031583-A The liquid-phase chromatography method of separation determination N- succinyl tryptophan enantiomter 浙江工业大学 2019-07-19 CN claimed
EP-1905763-B1 N-ACYLIC AMINOACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACOLOGICAL COMPOSITION AND THE USE IN THE FORM OF ANTI-ALLERGIC, ANTI-INFLAMMATORY AND HYPOLIPIDEMIC AGENTS NEBOLSIN VLADIMIR EVGENIEVICH (RU) 2019-05-08 EP claimed
US-8940780-B2 N-acylic aminoacid derivatives, method for the production thereof, pharmacological composition and the use in the form anti-allergic, anti-inflammatory and hypolipidemic agents OTKRYTOE AKTSIONERNOE OBSCHESTVO OTECHESTVENNYE LEKARSTVA (RU) 2015-01-27 US claimed
US-20080319040-A1 N-Acylic Aminoacid Derivatives, Method For The Production Thereof, Pharmacological Composition And The Use In The Form Anti-Allergic, Anti-Inflammatory And Hypolipidemic Agents OTKRYTOE AKTSIONERNOE OBSCHESTVO "OTECHESTVENNYE LEKARSTVA (RU) 2008-12-25 US claimed
EP-1905763-A1 N-ACYLIC AMINOACID DERIVATIVES. METHOD FOR THE PRODUCTION THEREOF, PHARMACOLOGICAL COMPOSITION AND THE USE IN THE FORM OF ANTI-ALLERGIC, ANTI-INFLAMMATORY AND HYPOLIPIDEMIC AGENTS Nebolsin, Vladimir Evgenievich (RU) 2008-04-02 EP claimed
US-20240366738-A1 MOLECULAR VACCINES FOR INFECTIOUS DISEASE AGILENT TECHNOLOGIES INC (US) 2024-11-07 US disclosed
CN-118147247-A Food flavoring compound succinyl amino acid and preparation method thereof 华南理工大学 2024-06-07 CN disclosed
US-11992518-B2 Molecular vaccines for infectious disease AGILENT TECHNOLOGIES, INC. (US) 2024-05-28 US disclosed
CN-110031583-B Liquid chromatography method for separating and measuring N-succinyl tryptophan enantiomer 浙江工业大学 2022-01-18 CN disclosed
US-10968269-B1 MHC multimers in borrelia diagnostics and disease AGILENT TECHNOLOGIES, INC. (US) 2021-04-06 US disclosed
US-20210047383-A1 MHC Multimers in Borrelia Diagnostics and Disease DAKO DENMARK APS (DK) 2021-02-18 US disclosed
US-20200347103-A1 MHC MULTIMERS IN TUBERCULOSIS DIAGNOSTICS, VACCINE AND THERAPEUTICS AGILENT TECHNOLOGIES INC (US) 2020-11-05 US disclosed
WO-2010037402-A1 MOLECULAR VACCINES FOR INFECTIOUS DISEASE DAKO DENMARK A/S (DK) 2010-04-08 WO disclosed
WO-2010037395-A2 MHC MULTIMERS IN CANCER VACCINES AND IMMUNE MONITORING DAKO DENMARK A/S (DK) 2010-04-08 WO disclosed
WO-2010037397-A1 MHC MULTIMERS IN CMV IMMUNE MONITORING DAKO DENMARK A/S (DK) 2010-04-08 WO disclosed
WO-2009106073-A2 MHC MULTIMERS IN BORRELIA DIAGNOSTICS AND DISEASE DAKO DENMARK A/S (DK) 2009-09-03 WO disclosed
WO-2009039854-A2 MHC MULTIMERS IN TUBERCULOSIS DIAGNOSTICS, VACCINE AND THERAPEUTICS DAKO DENMARK A/S (DK) 2009-04-02 WO disclosed
US-20080319040-A1 N-Acylic Aminoacid Derivatives, Method For The Production Thereof, Pharmacological Composition And The Use In The Form Anti-Allergic, Anti-Inflammatory And Hypolipidemic Agents OTKRYTOE AKTSIONERNOE OBSCHESTVO "OTECHESTVENNYE LEKARSTVA (RU) 2008-12-25 US disclosed
EP-1905763-A1 N-ACYLIC AMINOACID DERIVATIVES. METHOD FOR THE PRODUCTION THEREOF, PHARMACOLOGICAL COMPOSITION AND THE USE IN THE FORM OF ANTI-ALLERGIC, ANTI-INFLAMMATORY AND HYPOLIPIDEMIC AGENTS Nebolsin, Vladimir Evgenievich (RU) 2008-04-02 EP disclosed
WO-2003020900-A2 COMPOSITIONS AND METHODS RELATING TO BREAST SPECIFIC GENES AND PROTEINS DIADEXUS, INC. (US) 2003-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319040-A1 N-Acylic Aminoacid Derivatives, Method For The Production Thereof, Pharmacological Composition And The Use In The Form Anti-Allergic, Anti-Inflammatory And Hypolipidemic Agents HRH4, HRH2, AADAT DNMT1 4804/4885KMT2A 1759/4885PKM 4226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.